460 related articles for article (PubMed ID: 27978798)
1. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
2. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
3. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
4. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
5. Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy.
Yusoh NA; Ahmad H; Gill MR
ChemMedChem; 2020 Nov; 15(22):2121-2135. PubMed ID: 32812709
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Brown JS; O'Carrigan B; Jackson SP; Yap TA
Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
8. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Ngoi NYL; Westin SN; Yap TA
Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
[TBL] [Abstract][Full Text] [Related]
9.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA Damage Response in Prostate and Breast Cancer.
Wengner AM; Scholz A; Haendler B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
[TBL] [Abstract][Full Text] [Related]
11. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
Criscuolo D; Morra F; Giannella R; Visconti R; Cerrato A; Celetti A
J Exp Clin Cancer Res; 2019 Feb; 38(1):91. PubMed ID: 30791940
[TBL] [Abstract][Full Text] [Related]
12. Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer.
Nasioudis D; George EM; Xu H; Kim H; Simpkins F
Cancer Treat Res; 2023; 186():189-206. PubMed ID: 37978137
[TBL] [Abstract][Full Text] [Related]
13. Directing the use of DDR kinase inhibitors in cancer treatment.
Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
[TBL] [Abstract][Full Text] [Related]
14. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
[TBL] [Abstract][Full Text] [Related]
15. Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.
Mavroeidi D; Georganta A; Panagiotou E; Syrigos K; Souliotis VL
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474014
[TBL] [Abstract][Full Text] [Related]
16. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Minchom A; Aversa C; Lopez J
Ther Adv Med Oncol; 2018; 10():1758835918786658. PubMed ID: 30023007
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application.
Xie H; Wang W; Qi W; Jin W; Xia B
Front Immunol; 2021; 12():661115. PubMed ID: 34712221
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA damage response pathways in cancer.
Groelly FJ; Fawkes M; Dagg RA; Blackford AN; Tarsounas M
Nat Rev Cancer; 2023 Feb; 23(2):78-94. PubMed ID: 36471053
[TBL] [Abstract][Full Text] [Related]
19. Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons.
Bright SJ; Flint DB; Martinus DKJ; Turner BX; Manandhar M; Ben Kacem M; McFadden CH; Yap TA; Shaitelman SF; Sawakuchi GO
Radiat Res; 2022 Oct; 198(4):336-346. PubMed ID: 35939823
[TBL] [Abstract][Full Text] [Related]
20. DNA REPAIR. Drugging DNA repair.
Jackson SP; Helleday T
Science; 2016 Jun; 352(6290):1178-9. PubMed ID: 27257245
[No Abstract] [Full Text] [Related]
[Next] [New Search]
